Pierre Laurin Sells 82,738 Shares of ProMetic Life Sciences Inc. (PLI) Stock

ProMetic Life Sciences Inc. (TSE:PLI) Director Pierre Laurin sold 82,738 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of C$1.45, for a total value of C$119,970.10.

Pierre Laurin also recently made the following trade(s):

  • On Wednesday, September 13th, Pierre Laurin sold 82,738 shares of ProMetic Life Sciences stock. The shares were sold at an average price of C$1.44, for a total value of C$119,142.72.
  • On Thursday, September 7th, Pierre Laurin sold 41,427 shares of ProMetic Life Sciences stock. The shares were sold at an average price of C$1.45, for a total value of C$60,069.15.

ProMetic Life Sciences Inc. (TSE PLI) opened at 1.43 on Friday. The firm’s 50-day moving average price is $1.42 and its 200-day moving average price is $1.87. ProMetic Life Sciences Inc. has a 1-year low of $1.12 and a 1-year high of $3.24. The firm’s market cap is $1.01 billion.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/09/17/pierre-laurin-sells-82738-shares-of-prometic-life-sciences-inc-pli-stock-2.html.

PLI has been the subject of several research reports. Royal Bank Of Canada restated an “outperform” rating on shares of ProMetic Life Sciences in a research note on Wednesday, May 24th. Canaccord Genuity reduced their target price on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating for the company in a research note on Monday, June 19th. Scotiabank reduced their target price on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating for the company in a research note on Friday, July 7th. TD Securities reduced their target price on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a research note on Wednesday, August 16th. Finally, National Bank Financial raised their target price on ProMetic Life Sciences from C$2.00 to C$2.50 in a research note on Wednesday, August 30th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. ProMetic Life Sciences has an average rating of “Buy” and an average target price of C$3.60.

About ProMetic Life Sciences

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Insider Buying and Selling by Quarter for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply